Getting Here & Around

Bronchopulmonary dysplasia (BPD) is a chronic lung disease of premature infants characterized by marked inflammation and alveolar hypoplasia.  Presently there are no known medications which prevent the development of BPD.   The purpose of the present study is to evaluate the ability of a single intratracheal dose of recombinant human CC10 to prevent the development of long-term respiratory complications and BPD in ventilated premature infants. 

The purpose of this research study is to compare treatment options for infants with Neonatal Abstinence Syndrome (NAS) due to narcotic exposure in the womb and evaluate the effects of treatment on long-term neurodevelopmental outcome at 18 months of age. The goal is to compare the two most commonly used drugs and see which requires fewer days in the hospital to complete treatment.  The study will also determine if genetic variations contribute to the severity of NAS.

The purpose of this study is to demonstrate that the safety and effectiveness of the Medtronic Transcatheter Aortic Valve Replacement (TAVR) system as measured by rates of all-cause mortality or disabling stroke at two years is non-inferior to Surgical Aortic Valve Replacement (SAVR) in the treatment of severe aortic stenosis in subjects who have a low predicted risk of operative mortality for SAVR.

The purpose of this study is to evaluate the safety and efficacy of the study drug, FS VH S/D 500 s-apr, compared to DuraSeal Dural Sealant as an additional aid to sutured dural (membrane that covers and protects the brain and spinal cord) closure.

The purpose of this study is to determine if quantitative analysis of fetal fibronectin can be used to advance prediction of spontaneous preterm birth.

The purpose of this study is to better understand how phthalates, compounds that disrupt hormones, affect embryonic development after fertilization.

Information on the safety and effectiveness of Restorelle Direct Fix and the surgical procedure to implant Restorelle polypropylene mesh in the repair of pelvic organ prolapse will be collected in this study.

The purpose of this study is to compare safety, efficacy, and tolerability of a two drug regimen of dolutegravir (DTG) plus (+) lamivudine (3TC) administered once daily to the DTG plus Tenofovir [TDF]/Emtricitabine [FTC] fixed dose combination [FDC] administered once daily in human immunodeficiency virus (HIV) 1 infected adult subjects that have not previously received antiretroviral therapy. The study is designed to demonstrate the non-inferior antiviral activity of DTG plus 3TC regimen to that of DTG plus TDF/FTC FDC.